Former execs from Pfizer obesity drug program have started a new biotech with $52M from VC fund ATP

Two former chemistry VPs who worked at Pfizer’s cardiovascular and metabolic research group have come together to build a new biotech as the obesity drug development field soars.

The startup, called Deep Apple Therapeutics, has a lead program that goes after an undisclosed inflammatory skin disease and will enter the…
Click here to view original post